Introduction
The myc family of proto-oncogenes, comprising c-myc, N-myc and L-myc, is involved in some of the most important cellular processes, such as cell proliferation, dierentiation, apoptosis and neoplastic phenomena (for reviews see Cole, 1986; Luscher and Eisenman, 1990; Evan and Littlewood, 1993; Amati and Land, 1994) . myc genes play a major role in human oncogenesis. The c-myc oncogene is implicated in a wide variety of human tumors, including Burkitt's lymphomas, in which it is speci®cally translocated (Bishop, 1987) and breast cancer, in which it is overexpressed in up to 45% of the tumors (Guerin et al., 1988) . N-myc is overexpressed in a more restricted set of malignancies, predominantly in neuroblastomas and related tumors, and L-myc is over-expressed in small cell lung carcinomas, both as a result of gene ampli®cation (Kohl et al., 1983; Schwab et al., 1983; Nau et al., 1985) .
myc genes maintain distinct expression patterns during embryonic development (Zimmerman et al., 1986) . It has been suggested that Myc proteins are involved in cellular dierentiation and recent evidence has shown that null-mutations of either c-myc or Nmyc are embryonically lethal (Charron et al., 1992; Stanton et al., 1992; Davis et al., 1993) . Thus, they probably play distinct roles in normal development. myc genes share the same exon structure and encode related nuclear phosphoproteins (Hann et al., 1983; Persson and Leder, 1984; Ramsay et al., 1984; DePinho et al., 1987; Hamann et al., 1991) . These proteins harbor structural motifs seen in a number of transcription factors (Landschultz et al., 1987; Murre et al., 1989; Prendergast and Zi, 1989) . It has been shown that c-, N-, and L-Myc proteins all can form heterodimers with the nuclear protein Max (Blackwood and Eisenman, 1991; Wenzel et al., 1991; Blackwood et al., 1992) and bind to the same speci®c DNA sequence, CACGTG (Blackwell et al., 1990; Alex et al., 1992; Ma et al., 1993) .
Thus, Myc proteins are transcription factors that are directly involved in the regulation of gene expression. Over the last few years, several genes have been found to be targets for c-Myc regulation in man and mouse (Schmidt, 1996) . All c-Myc target genes harbor the Myc-binding element, CACGTG, downstream to their start site of transcription (Ben-Yosef et al., 1996) . Whether c-Myc and N-Myc share the same targets, or regulate dierent genes, is not clear yet. Here we examine the involvement of c-Myc target genes in c-myc and N-myc induced human malignancies. Speci®cally, we looked at the following c-Myc targets: ECA39 (Benvenisty et al., 1992) , p53 (Ronen et al., 1991; Reisman et al., 1993) , ornithine decarboxylase (ODC) (Bello-Fernandez and Cleveland, 1992; BelloFernandez et al., 1993) , a-prothymosin (Gaubatz et al., 1994) and Cdc25A (Galaktionov et al., 1996) . We conclude that all of these targets are involved in c-myc induced human tumors. Moreover, they can be potentially regulated by N-Myc in vitro, but their expression seems to be regulated in a more complex manner in human tumors of neuronal origin.
over-expressed in up to 45% of breast tumors (Guerin et al., 1988) . To examine the involvement of c-myc and Myc targets in breast cancer cells, we analysed c-myc expression in three estrogen receptor-positive and one estrogen receptor-negative human breast cancer cell lines respectively) . High levels of c-myc mRNA were detected in all cell lines (data not shown). We chose the MCF-7 estrogen-dependent cell line (Lima and Shiu, 1985) for further investigation, since it has been shown previously that in these cells estrogen stimulates c-myc expression (Dubik et al., 1987; Dubik and Shiu, 1988) . This stimulation is maximized if, prior to the addition of estrogen, cells are arrested by the use of tamoxifen, a speci®c estrogen antagonist (Dubik et al., 1987) . We examined expression of the c-myc gene and of the known c-Myc target genes ± ECA39, Cdc25A, p53, ODC and a-prothymosin ± in MCF-7 cells, after treatment with tamoxifen (1610 76 M) followed by 17b-estradiol (1610 77 M). As expected, c-myc expression was signi®cantly stimulated after 17b-estradiol treatment, with maximal levels of c-myc mRNA accumulation (®vefold) achieved after 1 h (Figure 1) . A gradual decline in the level of c-myc mRNA was observed during the next 3 h, followed by a moderate increase (4twofold -8 h after 17b-estradiol addition) ( Figure  1 ). The expression of all the examined c-Myc targets was induced following 17b-estradiol addition. In a time course of 8 h, maximal induction of 2 ± 35-fold was detected for all mRNAs after 1 ± 2 h. By 8 h, a gradual decline followed by a moderate increase were also observed for ECA39, a-prothymosin and p53, while Cdc25A expression level remained high throughout this time course. The ODC induction ended by 4 h after 17b-estradiol treatment (Figure 1) . b-actin expression was not aected by estradiol (Figure 1) .
Expression of the c-myc gene and Myc targets in primary breast tumors
The results obtained from the MCF-7 cell line indicate that c-myc can induce the expression of its target genes in these breast cancer cells. We thus examined the involvement of c-myc and Myc targets in several primary breast tumors. Speci®cally, c-myc expression was analysed by reverse transcription and polymerase chain reaction (RT ± PCR) in ®ve pairs of breast tumors versus normal tissue. Three of the tumors exhibited c-myc over-expression (Figure 2 ): c-myc expression was four-, 13-and 450-fold higher than in the normal tissues (Figure 2a, b and c, respectively) . These results are in agreement with previous works, which indicated that c-myc is over-expressed in approximately half of breast tumors (Guerin et al., 1988) . The expression of several Myc target genes was examined in these tumors by RT ± PCR or by Northern blot hybridization. As shown in Figure 2 , ECA39, Cdc25A and p53 exhibited an average overexpression of six-, 10-and 410-fold, respectively, in the breast tumors in comparison to normal tissues. Only a slight increase in a-prothymosin expression was demonstrated, and ODC expression was in negligible levels in all of the tumors. b-actin expression served as an internal control ( Figure 2a 
Expression of c-Myc target genes in Burkitt's lymphomas
The best characterized example of c-myc involvement in human tumors is Burkitt's lymphoma. In this disease, the c-myc oncogene on chromosome 8 is joined to the immunoglobulin heavy chain locus on chromosome 14 as a result of a speci®c translocation which causes constitutive c-myc expression (for review see Rabbitts, 1994) . Thus, we examined the involvement of Myc targets in several Burkitt's and nonBurkitt's lymphoma cell lines. Human c-myc, ECA39, Cdc25A, p53, ODC and a-prothymosin expression was analysed by Northern blot hybridization or by reverse transcription and polymerase chain reaction (RT ± PCR) (Figure 3a ,b). As expected, high levels of both c-myc mRNA and c-Myc protein were found in the two Burkitt's lymphoma cell lines, Raji and DG-75 (Pulvertaft, 1965; Ben-Bassat et al., 1977) (Figure 3a,c) . As shown in Figure 3a and b, ECA39, Cdc25A, p53, ODC and a-prothymosin were expressed in the two Burkitt's lymphoma cell lines (Raji and DG-75), but not in the non-Burkitt's lymphoma cell line, (Farage), nor in a T-cell lymphoma cell line (HD-mar) (BenBassat et al., 1980 (BenBassat et al., , 1992 . Note that b-actin expression was detected in all RNA samples (Figure 3a,b) .
Expression of c-Myc target genes in a neuroepithelioma cell line overexpressing c-myc SK-N-MC is a neuroepithelioma cell line, which expresses high levels of c-myc (Yeger et al., 1988) . c-myc overexpression in this cell line was also con®rmed by Northern blot hybridization (Figure 4a , ®rst lane). We examined the expression of the c-Myc target genes in SK-N-MC cells by Northern blot hybridization or by RT ± PCR (Figure 4a ,b, ®rst lane). Out of the ®ve genes examined, only one (a- Figure 3 Expression of c-Myc target genes in Burkitt's lymphomas. (a) Total RNA was extracted from several Burkitt's and non-Burkitt's lymphoma cell lines. Using RT ± PCR techniques, we were able to detect high levels of c-myc expression in two Burkitt's lymphoma cell lines, Raji (Rj) and DG-75 (DG), and a lower level of expression in a non-Burkitt's lymphoma cell line, Farage (F). ECA39 (263 bp product) and Cdc25A (600 bp product) transcripts were detected in the two Burkitt's lymphoma cell lines: Raji and DG-75. No expression was found in the nonBurkitt's lymphoma cell line, Farage, or in a T-cell lymphoma cell line, HD-mar (HD). b-actin served as an internal control. (b) Northern blot analysis with speci®c labeled DNA probes for p53, ODC and a-prothymosin showed expression of these genes in the two Burkitt's lymphoma cell lines: Raji (Rj) and DG-75 (DG). None of these genes was found to be expressed in the nonBurkitt's lymphoma cell line, Farage (F) or in the T-cell lymphoma cell line, HD-mar (HD). b-actin served as an internal control. (c) Western blot analysis was performed using 10 mg protein of nuclear extract from several lymphoma cell lines. A speci®c anti-c-Myc monoclonal antibody detected c-Myc protein in two Burkitt's lymphoma cell lines: Raji (Rj) and DG-75 (DG), but not in the non-Burkitt's lymphoma cell line, Farage (F), or in a T-cell lymphoma cell line, HD-mar (HD) Figure 4 Expression of c-Myc target genes in neuronal tumors. (a) Total RNA was extracted from several neuroblastoma (NB) and neuroepithelioma (NE) cell lines. Shown are Northern blots with speci®c c-myc, N-myc, ODC and a-prothymosin probes. b-actin served as an internal control. The histograms represent relative expression levels of these genes in the various cell lines. (b) Using RT ± PCR techniques, we were able to detect ECA39 (263 bp product) and Cdc25A (600 bp product) transcripts in some of the neuroblastoma cell lines. b-actin served as an internal control. The histograms represent relative expression levels of these genes in the various cell lines prothymosin) was found to be expressed at high levels in SK-N-MC cells, while for the others expression levels were very low (ECA39, Cdc25A and ODC), or undetectable (p53). b-actin served as an internal control (Figure 4a ,b, ®rst lane).
Activation of ECA39 by c-Myc and N-Myc
c-Myc and N-Myc are both transcriptional regulators which bind to the same DNA sequence (Blackwell et al., 1990; Alex et al., 1992) . Since N-myc is a major oncogene in neuroblastomas we examined whether the Myc targets can be activated by N-Myc instead of c-Myc in tumors of neuronal origin. We therefore ®rst examined whether promoters that are activated by c-Myc can also be activated by N-Myc. For this purpose we used a chimeric ECA39 ± CAT construct. This construct, named 2-0.6-ECA39-CAT, harbors the mouse ECA39 gene promoter region, including an intact Myc binding site, fused to the chloramphenicol acetyltransferase (CAT) reporter gene. It had been previously shown that expression of this chimeric gene is induced by over-expression of c-myc in COS cells (Benvenisty et al., 1992) . We transfected COS cells with the 2-0.6-ECA39-CAT construct, with or without c-myc or N-myc expression vectors. As shown in Figure 5 , the expression of the chimeric gene was similarly induced in the presence of either of the myc expression vectors (average induction level of 11-and 16-fold by c-Myc and N-Myc, respectively), suggesting that the ECA39 gene can be regulated by both c-Myc and N-Myc, through the same Myc-binding element, located in its 5'UTR.
Expression of c-Myc target genes in neuroblastoma cell lines
In the neuroepithelioma cell line no correlation was found between the expression of c-myc and its target genes. Since it has been shown that N-Myc binds the same speci®c DNA sequence as c-Myc, and we could demonstrate that at least one of the c-Myc target genes, ECA39, can be regulated in vitro by N-Myc, it was interesting to examine the expression of c-Myc targets in another type of neuronal tumors, neuroblastomas (NB). Ampli®cation of the N-myc gene and high levels of N-myc mRNA are known features of human NB tumors and their derived cell lines (Schwab et al., 1983) . For two of the analysed NB cell lines ampli®cation of the N-myc gene was previously reported: Kelly (100 ± 120-fold) and IMR-32 (15 ± 20-fold) (Schwab et al., 1983) . To con®rm the N-myc ampli®cation status in the NB cells, we used slot blot analysis ( Figure 6 ). The N-myc gene was found to be ampli®ed in the NB cell lines (Kelly, NHB and HDU-16) but not in the neuroepithelioma cell line, SK-N-MC (Yeger et al., 1988) (Figure 6 ). c-myc was not ampli®ed in either cell line (Figure 6 ). b-actin served as an internal control.
We examined the expression of the c-Myc target genes in NB cells by Northern blot hybridization or by RT ± PCR (Figure 4a,b) . Only one gene, ODC, was highly expressed in all four NB lines (Figure 4a ), while for the other genes examined, a more complex pattern of expression was found. ECA39 gene expression was detected in all cell lines, except NHB (Figure 4b ). aprothymosin expression was found in IMR-32, NHB and HDU-16, but not in the Kelly cell line (Figure 4a ). Expression levels of Cdc25A were high in NHB and HDU-16 cells, but very low in other cell lines ( Figure  4b ). b-actin expression was detected in all RNA samples (Figure 4a,b) . Discussion c-Myc target genes have been identi®ed and characterized primarily in the mouse (Schmidt, 1996) . Since Figure 5 Activation of ECA39 chimeric gene by c-Myc and N-Myc. COS cells were electroporated with the ECA39-CAT chimeric reporter gene (2-0.6-ECA39-CAT) with or without the addition of c-myc or N-myc expression vectors. The SV40-CAT chimeric construct served as a control. CAT activity was determined 36 h after transfection and the products were separated by thin-layer chromatography (Gorman et al., 1982) . C ± chloramphenicol; 1AC ± 1 acetyl chloramphenicol; 3AC ± 3 acetyl chloramphenicol; 1,3AC ± 1,3 acetyl chloramphenicol Figure 6 Analysis of N-myc ampli®cation in neuronal tumors. Genomic DNA was extracted from several neuroblastoma (NB) and neuroepithelioma (NE) cell lines. Slot blot analysis detected N-myc ampli®cation in the NB lines (Kelly, NHB and HDU-16) but not in the NE cell line (SK-N-MC). c-myc is not ampli®ed in these cell lines. b-actin served as an internal control c-myc is involved in human oncogenesis, we examined the expression of c-Myc targets in several types of human tumors, and initially used the MCF-7 breast cancer cell line. In these estrogen-dependent cells, c-myc transcription is directly induced within 1 h of treatment with 17b-estradiol (Dubik et al., 1987, and Figure 1 ). The ®rst rapid peak of c-myc induction is followed by a second moderate peak, which can be observed within several hours (Figure 1) . The expression of all the c-Myc targets that we examined was also stimulated in these cells following 17b-estradiol treatment (Figure 1) . The dierent patterns of expression exhibited by the various gene transcripts following the induction can be the result of dierence in their RNA stability in this system. It has been reported previously that ODC levels in MCF-7 cells are controlled by antiestrogens (Thomas et al., 1989) and that c-myc and p53 expression increase in these cells following estrogen treatment (Thompson et al., 1990) . It is likely that the increased expression of the ECA39, Cdc25A, p53, ODC and a-prothymosin genes, seen in MCF-7 cells after 17b-estradiol treatment, is a result of their induction by c-Myc, which is induced by estrogen. In addition, in three primary breast tumors exhibiting c-myc overexpression, several Myc target genes (ECA39, Cdc25A and p53) were also overexpressed ( Figure 2 ). This suggests that these genes can serve as c-Myc targets in human oncogenesis.
In Burkitt's lymphoma, one of the best studied examples of c-myc involvement in a human tumor, c-myc is over-expressed as a result of a speci®c translocation. No such over-expression is found in non-Burkitt's lymphoma or in T-cell lymphoma cell lines (Figure 3a,c) . A clear correlation was found between the expression of c-myc and the expression of its targets in the various lymphoma cell lines. It appears that c-Myc induces the expression of the examined target genes in the Burkitt's lymphoma cell lines (Figure 3a,b) . Similar results have been reported for the p53 gene by Roy et al. (1994) .
Further investigation suggested that overexpression of c-myc is not always sucient for the expression of its target genes. In a neuroepithelioma cell line, SK-N-MC, c-myc is overexpressed, and so is one of its target genes, a-prothymosin, but not ECA39, Cdc25A, p53 or ODC (Figure 4a ,b ®rst lane). This complexity may contribute to the variability of the oncogenic phenotype. This is further demonstrated in certain tumors, in which the main inducer of Myc targets is N-Myc and not c-Myc.
The c-myc and N-myc genes are highly conserved as distinct genes through evolution and maintain distinct expression patterns during development (Zimmerman et al., 1986 ), yet they share a number of common features: Both genes are involved in oncogenesis in man and mouse (Kohl et al., 1983; Schwab et al., 1983; Bishop, 1987; Guerin et al., 1988) ; null-mutations of either c-myc or N-myc cause embryonic death at the same developmental stage (Charron et al., 1992; Stanton et al., 1992; Davis et al., 1993) ; both Myc proteins are transcription factors, which form heterodimers with the nuclear protein Max (Blackwood and Eisenman, 1991; Wenzel et al., 1991; Blackwood et al., 1992) and bind to the same speci®c DNA sequence, CACGTG (Blackwell et al., 1990; Alex et al., 1992; Ma et al., 1993) . Based on these facts, it is possible that c-Myc and N-Myc regulate the expression of the same genes. Yet, these oncogenes are involved in distinct tumor types. c-myc is frequently involved in tumors such as breast carcinoma and Burkitt's lymphoma, and N-myc is commonly involved in neuroblastomas. Thus, they might have distinct target genes in dierent tissues, or they may have both common and unique targets.
As shown in Figure 5 , the expression of a chimeric ECA39-CAT construct in COS cells was similarly induced by either c-Myc or N-Myc. These results suggest that the ECA39 gene can be regulated by both c-Myc and N-Myc, through the same Myc-binding element. We thus set out to examine the expression of c-Myc targets in another type of tumor, neuroblastomas (NB). Unlike their closely related variants, neuroepitheliomas, that express high c-myc levels, NB are usually characterized by ampli®cation and overexpression of the N-myc gene (Schwab et al., 1983; Yeger et al., 1988) . Expression of c-Myc targets could be detected in several NB cell lines, but the expression pattern was complex (Figure 4a,b) . Surprisingly, a clear correlation with N-myc expression was found only for the ODC gene. This gene was highly expressed in all four NB cell lines, but not in the neuroepithelioma cell line, in which c-myc, but not N-myc, was overexpressed (Figure 4a ). ODC and N-myc co-ampli®cation in NB cells has been reported in some cases, probably as a result of their proximal chromosomal localization (Tonin et al., 1989; Chen and Chen, 1991) . This can not explain the ODC overexpression found in our cell lines, since the ODC gene is not ampli®ed in these cell lines, as con®rmed by slot blot analysis (data not shown). Moreover, increased expression of the ODC gene, following conditional N-myc expression, was reported in a NB cell line which lacks N-myc ampli®cation (Lutz et al., 1996) . Taken together, these results may indicate that although the ODC gene was originally identi®ed as a target for c-Myc regulation, in neuronal tumors N-Myc, and not c-Myc, may be the natural regulator of ODC expression. As for the other c-Myc targets, no clear pattern could be established, since their expression was detected in some cell lines, but not in others (Figure 4a,b) . Correlation between N-myc mRNA levels and p53 or a-prothymosin expression in NB was previously reported (Raschella et al., 1991; Lutz et al., 1996) . Our ®ndings suggest that those genes, and other genes known as c-Myc targets, may be regulated by N-Myc, but that this is not the case in every cell or tumor type. It is most likely that in certain tumors other transcriptional regulators, which are probably in¯uenced by cell type and clone speci®city, are involved in regulation of Myc targets.
The proteins encoded by Myc target genes can be classi®ed, based on their function and sub-cellular localization, into two main categories: nuclear proteins, which are involved in cell cycle regulation, and cytoplasmic proteins, which are involved in nucleotide and amino acid metabolism. The ®rst group includes Cdc25A, a cell cycle phosphatase (Galaktionov and Beach, 1991) ; p53, a G 1 damage-induced checkpoint protein (Kuerbitz et al., 1992) ; and a-prothymosin, a nuclear protein that may play a role in mammalian cell proliferation (Eilers et al., 1991) . The second group includes ECA39, also known as cytosolic branched chain amino acid aminotransferase (cBCAT), an enzyme involved in metabolism of branched chain amino acids , and ODC, a ratelimiting enzyme of polyamine biosynthesis (Bowlin et al., 1986) . In this work we show that Myc targets are expressed in human tumors. It is therefore expected that the phenotype of c-myc oncogenesis will involve several pathways, e.g., metabolism and cell cycle control.
c-Myc onco-protein has been shown to induce both proliferation and apoptosis (Amati and Land, 1994) . c-Myc targets have also been implicated in one or both of these processes. It has been suggested that p53 directly mediates c-Myc induced apoptosis (Hermeking and Eick, 1994) ; ODC may mediate both proliferation and apoptosis of cells (Bowlin et al., 1986; Auvinen et al., 1992; Packham and Cleveland, 1994; Desiderio et al., 1995) ; a-prothymosin may play a role in mammalian cell proliferation (Eschenfeldt and Berger, 1986; Gomez-Marquez et al., 1989) ; Cdc25A, which has been shown to be a mitotic inducer, can also induce apoptosis in cells depleted of growth factors (Sadhu et al., 1990; Galaktionov et al., 1996) ; and ECA39, which is involved in cell proliferation (Schuldiner et al., 1996) , may also be involved in apoptosis (Eden and Benvenisty, unpublished data) . Because the dierent target genes are involved in both proliferation and apoptosis, it was interesting to examine whether all of them are expressed in myc induced tumors, which are highly proliferative in nature. Our work indicates involvement of these genes in myc oncogenesis, as suggested by their expression in Burkitt's lymphomas, breast cancer cells and some neuroblastomas (Figures 1, 2, 3 and 4) . These ®ndings suggest that if we could disturb the equilibrium of cMyc targets in certain tumors, the cells might be driven to undergo apoptosis, instead of proliferation.
Materials and methods

Cell lines and media
Human lymphoma cell lines were grown in suspension in RPMI-1640 medium supplemented with 10% fetal calf serum. Human neuroblastoma cell lines were grown in RPMI-1640 medium supplemented with 15% fetal calf serum. COS and MCF-7 cells were grown in Dulbecco's modi®ed Eagle medium (DMEM) supplemented with 10% fetal calf serum. All media were supplemented with 50 units/ml of penicillin G, 50 mg/ml of streptomycin and 4 mM L-glutamine. MCF-7 cells were treated with tamoxifen (Sigma Biosciences) and 17b-estradiol (Sigma Biosciences) as described previously (Dubik and Shiu, 1988) .
RNA and DNA isolation and analysis
Total RNA from cell lines and primary tumors was extracted with guanidine thiocyanate and centrifuged through a CsCl cushion by the method of Chirgwin et al. (1979) . Genomic DNA from neuroblastoma cell lines was extracted as described (Sambrook et al., 1989) . For slot blot analysis, 1.5 mg of genomic DNA from each neuroblastoma cell line were denaturated and ®xed to a NYTRAN membrane (Schleicher & Schuell), using a slot blot apparatus (Hoefer Scienti®c Instruments). Southern and Northern blot analyses were performed as described (Southern, 1975; Thomas, 1981) . DNA probes were radiolabeled by random priming (Feinberg and Vogelstein, 1983 ) using [a-32 ]PdCTP (3000 Ci/mmol, Rotem Industries, Israel).
RT ± PCR analysis cDNA was synthesized from 1 mg of total RNA, using random hexamer (pd(N) 6 ) as primer and M-MLV Reverse Transcriptase (Gibco BRL) (200 u). cDNA samples were subjected to PCR ampli®cation with speci®c ECA39, c-myc, Cdc25A and b-actin primers. The annealing temperature was 558C. PCR was performed under nonsaturating conditions, in order to re¯ect the original amount of the speci®c transcript. The primers used were: ECA39: CCACTGCATAGTGCAAAGCTG and CCAGT-CTAGACTATTTGCTCGG ± product: 263 bp; c-myc: ACTATGACCTCGACTACGACTC and CTGCAGGTA-CAAGCTGGAGGTG ± product: 680 bp; Cdc25A: CTA-CTGATGGCAAGCGTGTC and CACTGTGGCTCAG-AGCAGCTTG ± product: 600 bp; b-actin: TGAAACA-ACATACAATTCCATCATGAAGTGTGAC and AG-GAGCGATAATCTTGATCTTCATGGTGCT ± product: 174 bp.
Nuclear extracts and Western blot analysis
Nuclear extracts were prepared from cells as described by Lassar et al. (1991) . Western blot analysis was performed as described by Towbin et al. (1979) . Nuclear extract samples were loaded onto 10% SDS ± PAGE gels and transferred to nitrocellulose ®lters. Ab-2 mouse monoclonal anti-c-Myc antibody (Oncogene Research Products) was used at 1/500 dilution for c-Myc detection, and goat anti-mouse IgG conjugated to alkaline phosphatase (Sigma Biosciences) was used as secondary antibody.
Chimeric genes, transfection conditions and CAT assay
The 2-0.6-ECA39-CAT construct was previously described (Benvenisty et al., 1992) . The c-myc expression vector (pSV7hummyc, Murphy et al., 1986) , and the N-myc expression vector, harbor the c-myc or N-myc gene, respectively, driven by an SV40 promoter/enhancer. COS cells were used for transient transfection assays. DNA was transfected into cells by electroporation (960 mF, 250 V, Bio-Rad Gene Pulser) (Potter et al., 1984) . CAT activity was determined 36 ± 48 h after transfection, as described previously (Gorman et al., 1982) .
